-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Acadia Pharmaceuticals Inc quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2017 to Q3 2024.
- Acadia Pharmaceuticals Inc Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $6.04M, a 53.6% decline year-over-year.
- Acadia Pharmaceuticals Inc Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $8.19M, a 52.3% decline year-over-year.
- Acadia Pharmaceuticals Inc annual Income Tax Expense (Benefit) for 2023 was $10.3M, a 305% increase from 2022.
- Acadia Pharmaceuticals Inc annual Income Tax Expense (Benefit) for 2022 was $2.53M, a 621% increase from 2021.
- Acadia Pharmaceuticals Inc annual Income Tax Expense (Benefit) for 2021 was $351K, a 42.6% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)